These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 21385769)

  • 1. Changes in renal vessels following the long-term administration of an angiotensin II receptor blocker in Zucker fatty rats.
    Nakanishi K; Nagai Y; Honglan Piao ; Akimoto T; Kato H; Yanakieva-Georgieva N; Ishikawa Y; Yoshihara K; Ito K; Yamanaka N; Oite T
    J Renin Angiotensin Aldosterone Syst; 2011 Jun; 12(2):65-74. PubMed ID: 21385769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferative changes of renal arteriolar walls induced by administration of angiotensin II receptor blocker are frequent in juvenile rats.
    Nagai Y; Nakanishi K; Akimoto T; Yamanaka N
    J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):440-9. PubMed ID: 24222655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in renal vessels associated with long-term administration of angiotensin converting enzyme inhibitor in Zucker fatty rats.
    Nakanishi K; Nagai Y; Akimoto T; Yamanaka N
    J Smooth Muscle Res; 2017; 53(0):20-30. PubMed ID: 28260705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-time observation of glomerular hemodynamic changes in diabetic rats: effects of insulin and ARB.
    Li B; Yao J; Kawamura K; Oyanagi-Tanaka Y; Hoshiyama M; Morioka T; Gejyo F; Uchiyama M; Oite T
    Kidney Int; 2004 Nov; 66(5):1939-48. PubMed ID: 15496165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of angiotensin II type 1 receptor blocker on triglyceride metabolism in the liver: experiment with Zucker fatty rats].
    Ran JM; Lao GC; Xu G; Xie B; Zhang Y; Liu W; Feng Q; Guo J
    Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(22):1557-61. PubMed ID: 18956640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
    Ohishi M; Takeya Y; Tatara Y; Yamamoto K; Onishi M; Maekawa Y; Kamide K; Rakugi H
    Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ANG II receptor blockade enhances anti-inflammatory macrophages in anti-glomerular basement membrane glomerulonephritis.
    Aki K; Shimizu A; Masuda Y; Kuwahara N; Arai T; Ishikawa A; Fujita E; Mii A; Natori Y; Fukunaga Y; Fukuda Y
    Am J Physiol Renal Physiol; 2010 Apr; 298(4):F870-82. PubMed ID: 20071465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.
    Pugsley MK
    Proc West Pharmacol Soc; 2005; 48():35-8. PubMed ID: 16416656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrarenal RAS activity and urinary angiotensinogen excretion in anti-thymocyte serum nephritis rats.
    Ohashi N; Yamamoto T; Huang Y; Misaki T; Fukasawa H; Suzuki H; Togawa A; Suzuki S; Fujigaki Y; Nakagawa T; Nakamura Y; Suzuki F; Kitagawa M; Hishida A
    Am J Physiol Renal Physiol; 2008 Nov; 295(5):F1512-8. PubMed ID: 18784264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Study of Morphological Changes in Renal Afferent Arterioles Induced by Angiotensin II Type 1 Receptor Blockers in Hypertensive Patients.
    Nagai Y; Yamabe F; Sasaki Y; Ishii T; Nakanishi K; Nakajima K; Shibuya K; Mikami T; Akasaka Y; Urita Y; Yamanaka N
    Kidney Blood Press Res; 2020; 45(2):194-208. PubMed ID: 31945766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II type I receptor blockade suppresses glomerular renin-angiotensin system activation, oxidative stress, and progressive glomerular injury in rat anti-glomerular basement membrane glomerulonephritis.
    Kinoshita Y; Kondo S; Urushihara M; Suga K; Matsuura S; Takamatsu M; Shimizu M; Nishiyama A; Kawachi H; Kagami S
    Transl Res; 2011 Oct; 158(4):235-48. PubMed ID: 21925120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure.
    Nishio M; Sakata Y; Mano T; Yoshida J; Ohtani T; Takeda Y; Miwa T; Masuyama T; Yamamoto K; Hori M
    J Hypertens; 2007 Feb; 25(2):455-61. PubMed ID: 17211254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renoprotective effects of an angiotensin II receptor blocker in experimental model rats with hypertension and metabolic disorders.
    Watanabe D; Tanabe A; Naruse M; Morikawa S; Ezaki T; Takano K
    Hypertens Res; 2009 Sep; 32(9):807-15. PubMed ID: 19662019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis.
    Mahmood J; Khan F; Okada S; Kumagai N; Morioka T; Oite T
    Kidney Int; 2006 Nov; 70(9):1591-8. PubMed ID: 16985512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of angiotensin II type-1 receptor increases salt sensitivity in Sprague-Dawley rats.
    Endo S; Mori T; Yoneki Y; Nakamichi T; Hosoya T; Ogawa S; Tokudome G; Hosoya T; Miyata T; Ito S
    Hypertens Res; 2009 Jun; 32(6):513-9. PubMed ID: 19407824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats.
    Izuhara Y; Sada T; Yanagisawa H; Koike H; Ohtomo S; Dan T; Ito S; Nangaku M; van Ypersele de Strihou C; Miyata T
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1767-73. PubMed ID: 18658044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term treatment of stroke-prone spontaneously hypertensive rats with an AT1 receptor blocker protects against hypertensive end-organ damage by prolonged inhibition of the renin-angiotensin system.
    Hamaguchi R; Takemori K; Inoue T; Masuno K; Ito H
    Clin Exp Pharmacol Physiol; 2008 Oct; 35(10):1151-5. PubMed ID: 18518883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor blockade inhibits acute glomerular injuries with the alteration of receptor expression.
    Mii A; Shimizu A; Masuda Y; Ishizaki M; Kawachi H; Iino Y; Katayama Y; Fukuda Y
    Lab Invest; 2009 Feb; 89(2):164-77. PubMed ID: 19139720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits.
    Arishiro K; Hoshiga M; Negoro N; Jin D; Takai S; Miyazaki M; Ishihara T; Hanafusa T
    J Am Coll Cardiol; 2007 Apr; 49(13):1482-9. PubMed ID: 17397679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.